The effects of long-term reserpine therapy (1) on cardiac output during rest and induced atrial tachycardia and (2) on atrioventricular (A-V) conduction were examined in a group of eight men with previously untreated essential hypertension. The patients were studied before and after 20 to 205 days of reserpine therapy. All studies were performed in the cardiopulmonary laboratory with the patients supine. Heart rate was controlled with a transvenous pacing catheter and a battery-powered pacemaker. After therapy six of six patients had a fall in cardiac output with a statistically significant difference (P < 0.001) between the means of paired pre-reserpine and reserpine cardiac outputs during both rest and paced tachycardia. At comparable heart rates, atrioventricular conduction increased in six of eight patients following reserpine, and a significant difference (P < 0.05) was evident when the means of pooled paired pre-and postreserpine A-V conductions were compared.
Of particular interest were (1) the effects of reserpine on cardiac output during rest and induced atrial tachyeardia and (2) the effects of reserpine on atrioventricular (A-V) conduction. This information was considered to be of practical importance in view of the extensive use of reserpine in the treatment of an illness which may, in its natural course, result in hypertensive or coronary heart disease2,3 with attendant compromise in hemodynamic and electrophysiological function.
causes of hypertension. A diagnosis of established hypertension was made if average arm cuff blood pressure recordings were more than 150/90 during 2 weeks' observation. 4 No patient had symptoms of arteriosclerotic heart disease or evidence of congestive heart failure. Resting electrocardiograms were abnormal in five patients, and exercise tolerance tests produced "ischemic RS-T segment depression"5' 6 of more than 1 mm in two additional subjects.
Seven patients were studied before and after an average of 31 days of reserpine therapy (range, 20 to 48 days); the reserpine was administered in daily oral doses of either 0.25 or 0.50 mg. The mean total dose was 11.61 mg (range, 7.5 to 16.5 mg). The remaining patient was followed for 205 days while he was receiving 0.50 mg of reserpine per day. If a greater reduction of blood pressure was required after daily doses of 0.50 mg of reserpine, the patient was restudied prior to the addition of other antihypertensive medication. At least 24 hours prior to the first study, each patient was introduced to all participating personnel and was familiarized with the setting of the cardiopulmonary suite.
All studies were performed in the cardiopulmonary laboratory with the patient supine and in a nonsedated, post-absorptive state. Utilizing 1% procaine anesthesia, a no. 7 transvenous luminal pacing catheter* was introduced percutaneously into an antecubital vein. It was then positioned against the lateral wall of the right atrium with fluoroscopic and electrocardiographic guidance. A battery-powered pacemaker (Medtronic "R" wave pulse generator model 5837) was utilized as a power source. It delivered impulses of 2-msec duration at an amperage which was adjusted between 2 and 7 ma to ensure reliable atrial "capture." The atrium was paced for 2-min intervals at rates which were started at slightly faster than the sinus rate and which were raised to a maximal rate of 150 beats/min or to the point of second degree A-V block.
A no. appearance of second degree A-V block at slightly higher rates. After 5 min of fixed paced heart rate, cardiac output was again determined. The patients experienced no subjective changes during the induced tachycardia.
All recordings were made on an Electronics for Medicine photographic oscilloscopic recorder. Cardiac outputs were obtained in duplicate and were determined from the inscribed curves by use of the Stewart-Hamilton formula.
A-V conduction time was determined from simultaneous standard electrocardiographic leads at a recording speed of 100 mm/sec. Intra-atrial electrocardiograms were recorded when a tripolar pacing catheter was utilized. For the sake of uniformity, pacemaker stimulus to onset of R wave was assumed to correspond to A-V conduction time. This assumption was based on the fact that there was no apparent delay from stimulus artifact to the onset of P waves as recorded during this and other studies7 by standard electrocardiographic leads and intra-atrial electrocardiograms. Blood pressures were recorded at the start and end of each study by the arm cuff method. Careful attention was given to proper grounding of all equipment and to the avoidance of handling the terminal poles of the electrode catheter during fluoroscopy.
Results
The results are summarized in tables 1 and 2. Comparative A-V conduction times were obtained in eight patients, of whom six had comparative cardiac output determinations. Table 2 Pt. were 3.66 ± 0.39 L/min/m2 and 2.76 + 0.39 L/min/m2. There was also a significant difference (P <0.001) between the means of these paired cardiac outputs ( fig. 1 ).
Atrioventricular Conduction
At comparable heart rates, A-V conduction time increased in six of eight patients during reserpine therapy (table 2, fig. 2 ). In one of CARDIAC OUTPUT (L/min.) 1 I the two remaining patients (C), A-V conduction time inconsistently increased over a full range of heart rates. In the other patient (H) although the P-R interval was not increased at a paced heart rate of 100, a rate of 110 beats/min resulted in markedly prolonged A-V conduction. Second degree block occurred before the next comparable rate could be reached. A significant difference (P < 0.05) was found between the pooled control and pooled reserpine A-V conduction times at comparable rates* (fig. 3) . The average pooled change for all patients was + 53 msec with a range of 0 to 164 msec.
Atrioventricular block occurred at slower paced heart rates after reserpine in five of the eight patients. The average decrease was 14 beats/min for the entire group (range, 0 to -40 beats/min).
Heart Rate
Resting heart rate fluctuated slightly (+ 4 beats/min) in six patients, with an equal incidence of increasing and decreasing rates.
The two remaining patients had decreases of 12 and 17 beats/min, respectively.
Discussion
Reserpine is a drug widely used in the treatment of hypertension. This study indicates that therapeutically administered reserpine in a hypertensive population may (1) significantly lower CO at rest with no further decrease during induced atrial tachycardia, (2) increase A-V conduction, and (3) enhance second degree heart block during induced atrial tachycardia. Figure 3 A-V conduction time following reserpine. A statistically significant increase in pooled A-V conduction time at comparable heart rates is noted after reserpine therapy.
Circulation, Volume XXXVII, free of evidence of arteriosclerotic heart disease. Cardiac output was determined by the indicator-dilution method before and 4 hours after drug administration. The only significant difference between the reserpine group and a control group was a fall in mean blood pressure. It should be emphasized that this population had labile hypertension and the selection criteria included absence of evident arteriosclerotic heart disease. These authors qualify the study as not relating "to the changes that take place during chronic oral administration of reserpine."
The long-term effects of oral administration of reserpine (Serpasil) and Rauwolfia serpentina (Raudixin) were sought by Cotten and associates" in 98 hypertensive patients, 79% of whom had "clinical, ECG, or x-ray evidence of heart disease." Fifty-eight of these patients had a reduction of cardiac output as determined by the Starr formula (stroke volume = 100 + 0.5 pulse pressure -0.6 diastolic blood pressure -0.61 age. CO = stroke volume x average pulse rate). These investigators stated that "the validity of the formula devised by Starr for determining cardiac output by blood pressure and age remains to be proven." This formula later was shown inaccurate in a heterogeneous group of hospital patients. '2 It can be appreciated from this brief review of previous investigations that the present study differs in design with respect to duration and route of reserpine therapy, nonexclusion of patients because of arteriosclerotic or hypertensive cardiovascular disease, and accepted methodology for determining cardiac output. We suggest that the consistent decline in cardiac output found in the present study was a result of these considerations.
Reserpine in clinical dosage may effectively deplete myocardial catecholamine content. Chidsey and associates'3 found a striking lowering of atrial appendage norepinephrine stores in a group of nonhypertensive patients receiving oral doses of reserpine prior to open heart surgery. Myocardial catecholamines, which are essential to a functionally intact adrenergic nervous system, appear to be of Circulation, Volume XXXVII, little importance to the normal organism in the basal state.14 Adverse hemodynamic effects of catecholamine depletion in resting man have been reported in patients with congestive heart failure. After guanethedine administration, congestive heart failure was intensified in the more severe cases. 15 The patient free of congestive heart failure with hypertensive cardiovascular disease or arteriosclerotic heart disease may be more dependent than normal persons on catecholamine stores in order to maintain basal hemodynamics.
An alternate mechanism to explain the consistent fall in cardiac output noted in our study is the effectiveness of reserpine in decreasing peripheral venous resistance and in diminishing venous return. '6 Mean arterial pressure was not directly recorded in this study, therefore an accurate statement cannot be made regarding changes in total peripheral resistance following reserpine therapy.
Tachycardia and Cardiac Output
Acceleration of heart rate after several minutes of atrial pacing in normal subjects does not alter cardiac output. '7-20 This finding was once again demonstrated in the present series of pre-reserpine control measurements (fig. 4) .
The effect of induced tachycardia on cardiac output in the catecholamine-depleted heart was a question of great Innes and associates32 noted a prolongation of A-V conduction time and functional refractory period of atrioventricular transmission in the canine heart-lung preparation. This finding was attributed to a direct effect of reserpine rather than to depletion of norepinephrine.
Several reports have noted a decrease in the ventricular response during atrial fibrillation in patients who have received reserpine or guanethidine.'5' 33' 34 After a detailed study of atrial rates and ventricular response during atrial fibrillation, Modell and Hussar33 concluded that "the only simple and reasonable explanation for the ventricular slowing is depression of A-V conduction by reserpine." Gaffney and Braunwald'5 concluded that the conductive properties of the A-V conduction system had been adversely affected by guanethidine. The mechanism was presumed to be an increase in the refractory period of the A-V conduction system following depletion of myocardial catecholamine stores as well as withdrawal of adrenergic stimuli.
The present study provides additional evidence that reserpine prolongs A-V conduction presumably by the same mechanism advanced by Gaffney and Braunwald. Increased A-V conduction time was noted in six of eight patients following reserpine administration during all comparable paced heart rates. In Circulation, Volume XXXVII, May 1968 addition, the total group demonstrated a significant difference between pooled pre-reserpine and reserpine A-V conduction times at comparable heart rates (P <0.05) ( fig. 3) .
Further evidence of the adverse effects of reserpine therapy on the functional integrity of A-V conduction was provided by the appearance of second degree A-V block at slower paced heart rates in five of the eight patients following treatment.
These changes in A-V conduction indicate that a potential source of clinical difficulty exists when reserpine is administered to a patient with a pre-existing A-V conduction disturbance or when reserpine is used in combination with other agents known to, increase A-V conduction time. Existing reports pertaining to both animal and clinical observations have made reference to this danger.27 3 
